Name (Synonyms) | Correlation | |
---|---|---|
drug2839 | hydrocortisone Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D011665 | Pulmonary Valve Insufficiency NIH | 0.41 |
D013577 | Syndrome NIH | 0.11 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
There is one clinical trial.
This is a randomized, double-blind, placebo-controlled, single-ascending dose study of AVM0703 administered as a single intravenous (IV) infusion to patients with COVID-19. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single-ascending dosing of AVM0703 in patients with COVID-19.
Description: The primary endpoint of the Phase 1 portion of the study is to evaluate the safety of AVM0703 in subjects with severe or life-threatening COVID-19 infection, and to identify the RP2D.
Measure: Dose-Limiting Toxicities Time: 0-12 monthsDescription: The primary endpoint of the Phase 1/2 portion of the study is to evaluate the efficacy of AVM0703 in subjects with severe or life-threatening COVID-19 infection.
Measure: 28 day all-cause mortality will be a primary end point for Phase 1 and 2 Time: 0-12 months